Test Location:
MRIGlobal

• Product : Active HEPA+
• Technologies: PCO/BPI/HEPA/ODOGard
• Test time: 3:20 minutes
• Air exchange equivalent: 10
• Test space: Class III Biosafety Cabinet, 2.5×3.5×1.5 ft
• Test location: MRIGlobal

These tests conclude that the Active HEPA+ is highly effective at reducing the infectivity of aerosolized SARS-CoV-2 virus with a 3.63 log (99.98%) reduction within three (3) minutes and twenty (20) seconds of operation in relation to baseline control results.

These results also show that HEPA+ had a reduction in aerosol mass and median size within the three (3) minutes and twenty (20) seconds of operation, with a mass removal of approximately 2 logs.

While particle mass reductions of only 2 logs were observed, Active HEPA+ demonstrated viral infectivity reductions greater than 3.5 logs, which supports the hypotheses that both active and passive technologies contribute to overall product efficacy.

Test Location:
MRIGlobal

• Product : pureAir 3000+
• Technologies: PCO/MERV/ODOGard
• Test time: 5:30 minutes
• Air exchange equivalent: 10
• Test space: Class III Biosafety Cabinet, 2.5×3.5×1.5 ft
• Test location: MRIGlobal

These tests conclude that the pureAir 3000+ is highly effective at reducing the infectivity of aerosolized SARS-CoV-2 virus with a 3.71 log (99.98%) reduction within five (5) minutes and thirty (30) seconds of operation in relation to baseline control results.

These results also show that 3000+ had a reduction in aerosol mass and median size within the five (5) minutes and thirty (30) seconds of operation, with a mass removal of approximately 1 log.

While particle mass reductions of only 1 log was observed, pureAir 3000+ demonstrated viral infectivity reductions greater than 3.5 logs, which supports the hypotheses that both active and passive technologies contribute to overall product efficacy.

Test Location:
MRIGlobal

• Product : pureAir HVAC
• Technologies: PCO/BPI
• Test time: 4 hours
• Surface type: Stainless steel
• Test space: Test chamber, 9x9x9 ft
• Test location: MRIGlobal

These tests conclude that the purAir HVAC PCO + BPI technology is effective at reducing surface SARS-CoV-2 infectivity in vitro after 4h of exposure.

Test samples had 0.89 log (86.98%) lower infectivity of SARS-CoV-2 as compared to control samples.

Test Location:
Microchem

• Product : pureAir HVAC
• Technologies: PCO/O3 (20%)
• Test time: 6 hours
• Surface type: Glass
• Test space: Test chamber
• Test location: Microchem

These tests conclude that the pureAir HVAC purAir HVAC PCO + O3 technology is effective at reducing surface MRSA infectivity in vitro after 6h of exposure.

Test samples had >4.75 log (>99.99%) lower infectivity of MRSA as compared to control samples.

Test also demonstrated that the pureAir HVAC technologies did not raise PPM of H2O2 or or O3 in the chamber during the experiment.

Test Location:
Microchem

• Product : pureAir HVAC
• Technologies: PCO/BPI/O3 (20%)
• Test time: 6 hours
• Surface type: Glass
• Test space: Test chamber
• Test location: Microchem

These tests conclude that the pureAir HVAC purAir HVAC PCO + BPI + O3 technology is effective at reducing surface MRSA infectivityin vitro after 6h of exposure.

Test samples had 1.26 log (93.9%) lower infectivity of MRSA as compared to control samples.

Test also demonstrated that the pureAir HVAC technologies did not significantly raise PPM of H2O2 or or O3 in the chamber during the experiment.

Test Location:
Microchem

• Product : pureAir HVAC
• Technologies: PCO/BPI
• Test time: 6 hours
• Surface type: Glass
• Test space: Test chamber
• Test location: Microchem

These tests conclude that the pureAir HVAC purAir HVAC PCO + BPI technology is effective at reducing surface MRSA infectivityin vitro after 6h of exposure.

Test samples had .61 log (69.6%) lower infectivity of MRSA as compared to control samples.

Test also demonstrated that the pureAir HVAC technologies did not raise PPM of H2O2 or or O3 in the chamber during the experiment.